Gyre Therapeutics (GYRE) Change in Account Payables (2014 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Change in Account Payables of $139000.0 for Q1 2026, up 892.86% year-over-year from $14000.0 in Q1 2025, and up 131.1% quarter-over-quarter from -$447000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Change in Account Payables (2014 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Change in Account Payables for 13 consecutive years, with $139000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 892.86% year-over-year to $139000.0; the TTM figure through Mar 2026 stood at $124000.0 (up 159.62% YoY), while the FY2025 annual figure was -$1000.0, up 99.59% from the prior year.
- Change in Account Payables advanced to $139000.0 in Q1 2026 per GYRE's latest filing, from -$447000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.3 million in Q4 2022 and bottomed at -$3.7 million in Q2 2022.
- Historically, Change in Account Payables has averaged -$1588.2 across 5 years, with a median of -$51000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 227.01% — and 2025, when it surged 1625.0%.
- Gyre Therapeutics' Change in Account Payables stood at $6.3 million in 2022, then slumped by 95.26% to $297000.0 in 2023, then slumped by 163.97% to -$190000.0 in 2024, then plunged by 135.26% to -$447000.0 in 2025, then surged by 131.1% to $139000.0 in 2026.
- Business Quant data shows GYRE's Change in Account Payables at $139000.0 in Q1 2026, -$447000.0 in Q4 2025, and $483000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 4.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.66 Mn |
| Mar 31, 2026 | 139,000.00 |
| Dec 31, 2025 | -433,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Jun 30, 2025 | 440,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | -190,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -23,000.00 |
| Dec 31, 2023 | -104,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 370,000.00 |
| Mar 31, 2023 | 156,000.00 |
| Dec 31, 2022 | 6.27 Mn |
| Sep 30, 2022 | -996,000.00 |
| Jun 30, 2022 | -3.67 Mn |
| Mar 31, 2022 | -1.71 Mn |
| Dec 31, 2021 | 2.56 Mn |
| Sep 30, 2021 | 2.03 Mn |